Your search for dabigatran returned 14 results

Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding

Despite trend toward lower stroke risk with high dose

For patients taking dabigatran, the risk of gastrointestinal bleeding (GIB) is reduced with use of gastroprotective agents.

For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time.

For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin vs. dabigatran etexilate (DE), according to a study published in the Journal of the American College of Cardiology.

For patients with atrial fibrillation receiving anticoagulant treatment, the presence of anemia is associated with increased risk of thromboembolic events, bleeding complications, and mortality.

Direct oral anticoagulants (DOACs) have distinct bleeding profiles and require individualized management approaches, according to a new review.

Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.

Almost all the various treatment options for acute venous thromboembolism are equally safe and effective, according to a new study.

Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a new study.